HIV stroke risk: Evidence and implications

Therapeutic Advances in Chronic Disease

Volumn 4, Issue 2, 2013, Pages 61-70

  Singer, Elyse J ^a   Valdes Sueiras, Miguel ^a   Commins, Deborah L ^b   Yong, William ^a   Carlson, Margrit ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Cerebrovascular; Human immunodeficiency virus type 1; Infection; Inflammation; Stroke

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALTEPLASE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; CYTOCHROME P450; DABIGATRAN ETEXILATE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; LIPID; LOPINAVIR PLUS RITONAVIR; MARAVIROC; METFORMIN; MEVINOLIN; NEVIRAPINE; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN ANTIBODY; RALTEGRAVIR; RITONAVIR; SIMVASTATIN; STAVUDINE; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRAMINE; WARFARIN;

AGING; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD CLOTTING DISORDER; BRAIN ARTERY ANEURYSM; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC INFLAMMATION; DIET THERAPY; DRUG EXPOSURE; DRUG METABOLISM; DYSLIPIDEMIA; ERADICATION THERAPY; EXERCISE; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTENSION; LIPID BLOOD LEVEL; LIPOATROPHY; LIPODYSTROPHY; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; RISK ASSESSMENT; SIDE EFFECT; SMOKING; SMOKING CESSATION; VASCULITIS;

EID: 84875537918     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622312471840     Document Type: Article

References (95)

1. Anders K. Steinsapir K. Iverson D. Glasgow B. Layfield L. Brown W. et al. (1986 a) Neuropathologic findings in the acquired immunodeficiency syndrome (AIDS). Clin Neuropathol 5: 1–20.
2. Anders K. Guerra W. Tomiyasu U. Verity M. Vinters H. (1986 b) The neuropathology of AIDS. UCLA experience and review. Am J Pathol 124: 537–558.
3. Annunziata P. (2003) Blood–brain barrier changes during invasion of the central nervous system by HIV-1. Old and new insights into the mechanism. J Neurol 250: 901–906.
4. Bedimo R. Westfall A. Drechsler H. Vidiella G. Tebas P. (2011) Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 53: 84–91.
5. Bell J. (1998) The neuropathology of adult HIV infection. Rev Neurol (Paris) 154: 816–829.
6. Berger J. Harris J. Gregorios J. Norenberg M. (1990) Cerebrovascular disease in AIDS: a case-control study. AIDS 4: 239–244.
7. Bergersen B. Sandvik L. Dunlop O. Birkeland K. Bruun J. (2003) Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 22: 731–736.
8. Bhagavati S. Choi J. (2008) Rapidly progressive cerebrovascular stenosis and recurrent strokes followed by improvement in HIV vasculopathy. Cerebrovasc Dis 26: 449–452.
9. Bissel S. Wiley C. (2004) Human immunodeficiency virus infection of the brain: pitfalls in evaluating infected / affected cell populations. Brain Pathol 14: 97–108.
10. Bozzette S. Ake C. Tam H. Chang S. Louis T. (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348: 702–710.
11. Busse K. Hadigan C. Chairez C. Alfaro R. Formentini E. Kovacs J. et al. (2009) Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. J Acquir Immune Defic Syndr 52: 235–239.
12. Calza L. Manfredi R. Chiodo F. (2004 a) Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 53: 10–14.
13. Calza L. Manfredi R. Chiodo F. (2004 b) Insulin resistance and diabetes mellitus in HIV-infected patients receiving antiretroviral therapy. Metab Syndr Relat Disord 2: 241–250.
14. Chow D. Souza S. Chen R. Richmond-Crum S. Grandinetti A. Shikuma C. (2003) Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 4: 411–416.
15. Chow F. Regan S. Feske S. Meigs J. Grinspoon S. Triant V. (2012) Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr 60: 351–358.
16. Cole J. Pinto A. Hebel J. Buchholz D. Earley C. Johnson C. et al. (2004) Acquired immunodeficiency syndrome and the risk of stroke. Stroke 35: 51–56.
17. Corral I. Quereda C. Moreno A. Perez-Elias M. Dronda F. Casado J. et al. (2009) Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors. Cerebrovasc Dis 27: 559–563.
18. Crane H. van Rompaey S. Kitahata M. (2006) Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 20: 1019–1026.
19. Cruciani M. Zanichelli V. Serpelloni G. Bosco O. Malena M. Mazzi R. et al. (2011) Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 25: 1993–2004.
20. Crum-Cianflone N. Tejidor R. Medina S. Barahona I. Ganesan A. (2008) Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDs 22:925–30.
21. Cutfield N. Steele H. Wilhelm T. Weatherall M. (2009) Successful treatment of HIV associated cerebral vasculopathy with HAART. J Neurol Neurosurg Psychiatry 80: 936–937.
22. d'Arminio A. Sabin C. Phillips A. Reiss P. Weber R. Kirk O. et al. (2004) Cardio- and cerebrovascular events in HIV-infected persons. AIDS 18: 1811–1817.
23. Dahl O. (2012) New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. Vasc Health Risk Manage 8: 45–57.
24. Dragovic G. Jevtovic D. (2012) The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV / AIDS patients. Biomed Pharmacother 66: 308–311.
25. Dubrovsky T. Curless R. Scott G. Chaneles M. Post M. Altman N. et al. (1998) Cerebral aneurysmal arteriopathy in childhood AIDS. Neurology 51: 560–565.
26. Duffy P. Wang X. Lin P. Yao Q. Chen C. (2009) HIV Nef protein causes endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells. J Surg Res 156: 257–264.
27. Engstrom J. Lowenstein D. Bredesen D. (1989) Cerebral infarctions and transient neurologic deficits associated with acquired immunodeficiency syndrome. Am J Med 86: 528–532.
28. Eugenin E. Morgello S. Klotman M. Mosoian A. Lento P. Berman J. et al. (2008) Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol 172: 1100–1111.
29. Ferketich A. Diaz P. Browning K. Lu B. Koletar S. Reynolds N. et al. (2012) Safety of varenicline among smokers enrolled in the Lung HIV Study. Nicotine Tob Res 15 May (Epub ahead of print).
30. Fichtenbaum C. Gerber J. (2002) Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 41: 1195–1211.
31. Fichtenbaum C. Gerber J. Rosenkranz S. Segal Y. Aberg J. Blaschke T. et al. (2002) Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16: 569–577.
32. Fischer-Smith T. Rappaport J. (2005) Evolving paradigms in the pathogenesis of HIV-1-associated dementia. Expert Rev Mol Med 7: 1–26.
33. Forastiero R. Martinuzzo M. Broze G. (2003) High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J Thromb Haemost 1: 718–724.
34. Galrao L. Brites C. Atta M. Atta A. Lima I. Gonzalez F. et al. (2007) Antiphospholipid antibodies in HIV-positive patients. Clin Rheumatol 26: 1825–1830.
35. Goldstein D. Timpone J. Cupps T. (2010) HIV-associated intracranial aneurysmal vasculopathy in adults. J Rheumatol 37: 226–233.
36. Gutierrez J. Glenn M. Isaacson R. Marr A. Mash D. Petito C. (2012) Thinning of the arterial media layer as a possible preclinical stage in HIV vasculopathy: a pilot study. Stroke 43: 1156–1158.
37. Hacke W. Kaste M. Bluhmki E. Brozman M. Davalos A. Guidetti D. et al. (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359: 1317–1329.
38. Hasse B. Ledergerber B. Furrer H. Battegay M. Hirschel B. Cavassini M. et al. (2011) Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 53: 1130–1139.
39. Henry K. Melroe H. Huebsch J. Hermundson J. Levine C. Swensen L. et al. (1998) Severe premature coronary artery disease with protease inhibitors. Lancet 351: 1328.
40. Ho J. Scherzer R. Hecht F. Maka K. Selby V. Martin J. et al. (2012) The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS 26: 1115–1120.
41. Hoffmann M. Berger J. Nath A. Rayens M. (2000) Cerebrovascular disease in young, HIV-infected, black Africans in the KwaZulu Natal province of South Africa. J Neurovirol 6: 229–236.
42. Huang M. Khan M. Garcia-Barrio M. Powell M. Bond V. (2001) Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp120. J Acquir immune Defic Syndr 27: 213–221.
43. Hunt P. (2012) HIV and inflammation: mechanisms and consequences. Curr HIV / AIDS Rep 9: 139–147.
44. Ingelheim B. (2011) Aptivus (tipranavir) US prescribing information. April. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021814s011lbl.pdf
45. Kanmogne G. Schall K. Leibhart J. Knipe B. Gendelman H. Persidsky Y. (2007) HIV-1 gp 120 compromises blood-brain barrier integrity and enhances monocyte migration across blood–brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab 27: 123–134.
46. Kieburtz K. Eskin T. Ketonen L. Tuite M. (1993) Opportunistic cerebral vasculopathy and stroke in patients with the acquired immunodeficiency syndrome. Arch Neurol 50: 430–432.
47. Kostapanos M. Milionis H. Elisaf M. (2010) Rosuvastatin-associated adverse effects and drug–drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 10: 11–28.
48. Liedtke M. Rathbun R. (2010) Drug interactions with antiretrovirals and warfarin. Exp Opin Drug Saf 9: 215–223.
49. Longo-Mbenza B. Longokolo Mashi M. Lelo Tshikwela M. Mokondjimobe E. Gombet T. Ellenga-Mbolla B. et al. (2011) Relationship between younger age, autoimmunity, cardiometabolic risk, oxidative stress, HAART, and ischemic stroke in Africans with HIV/AIDS. ISRN Cardiol 2011: 897908.
50. Lorenz M. Stephan C. Harmjanz A. Staszewski S. Buehler A. Bickel M. et al. (2008) Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 196: 720–726.
51. Malvestutto C. Aberg J. (2011) Management of dyslipidemia in HIV-infected patients. Clin Lipidol 6: 447–462.
52. Maniar A. Ellis C. Asmuth D. Pollard R. Rutledge J. (2012) HIV infection and atherosclerosis: evaluating the drivers of inflammation. Eur J Prev Cardiol 6 August (Epub ahead of print).
53. Manner I. Baekken M. Oektedalen O. Os I. (2012) Hypertension and antihypertensive treatment in HIV-infected individuals. A longitudinal cohort study. Blood Press 21: 311–319.
54. McGuire D. So Y. (1994) Intracranial disorders. In: Ed. Cohen P. Sande M. Volberding P. (eds), The AIDS Knowledge Base, 2nd ed. Boston, MA: Little, Brown & Co., pp. 5.7–5.8.
55. Mizusawa H. Hirano A. Llena J. Shintaku M. (1988) Cerebrovascular lesions in acquired immune deficiency syndrome (AIDS). Acta Neuropathol 76: 451–457.
56. Mochan A. Modi M. Modi G. (2003) Stroke in black South African HIV-positive patients: a prospective analysis. Stroke 34: 10–15.
57. Mochan A. Modi M. Modi G. (2005) Protein S deficiency in HIV associated ischaemic stroke: an epiphenomenon of HIV infection. J Neurol Neurosurg Psychiatry 76: 1455–1456.
58. Morris J. Singh S. Fisher M. (2010) Testing for inherited thrombophilias in arterial stroke: can it cause more harm than good? Stroke 41: 2985–2990.
59. Mu H. Chai H. Lin P. Yao Q. Chen C. (2007) Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg 31: 632–643.
60. Murphy R. Berzins B. Zala C. Fichtenbaum C. Dube M. Guaraldi G. et al. (2010) Change to atazanavir / ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS 24: 885–890.
61. Nagel M.A. Mahalingam R. Cohrs R.J. Gilden D. (2010) Virus vasculopathy and stroke: an under-recognized cause and treatment target. Infect Disord Drug Targets 10 (2):105–11.
62. Neuhaus J. Jacobs D. Baker J. Calmy A. Duprez D. La Rosa A. et al. (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 201: 1788–1795.
63. Oliveira J. Rondo P. (2011) Omega-3 fatty acids and hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: systematic review and meta-analysis. HIV Clin Trials 12: 268–274.
64. Oliviero U. Bonadies G. Apuzzi V. Foggia M. Bosso G. Nappa S. et al. (2009) Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis 204: 586–589.
65. Ovbiagele B. Nath A. (2011) Increasing incidence of ischemic stroke in patients with HIV infection. Neurology 76: 444–450.
66. Paik I. Kotler D. (2011) The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Research Clin Endocrinol Metab 25: 469–478.
67. Park I. Ullrich C. Schoenberger E. Ganju R. Groopman J. (2001 a) HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol 167: 2766–2771.
68. Park I. Wang J. Groopman J. (2001 b) HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood 97: 352–358.
69. Park Y. Belman A. Kim T. Kure K. Llena J. Lantos G. et al. (1990) Stroke in pediatric acquired immunodeficiency syndrome. Ann Neurol 28: 303–311.
70. Patsalides A. Wood L. Atac G. Sandifer E. Butman J. Patronas N. (2002) Cerebrovascular disease in HIV-infected pediatric patients: neuroimaging findings. AJR Am J Roentgenol 179: 999–1003.
71. Penzak S. Chuck S. (2002) Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs 2: 91–106.
72. Perriens J. Mussa M. Luabeya M. Kayembe K. Kapita B. Brown C. et al. (1992) Neurological complications of HIV-1-seropositive internal medicine inpatients in Kinshasa, Zaire. J Acquir Immune Defic Syndr 5: 333–340.
73. Peyriere H. Eiden C. Macia J. Reynes J. (2012) Antihypertensive drugs in patients treated with antiretrovirals. Ann Pharmacother 46: 703–709.
74. Pinto A. (1996) AIDS and cerebrovascular disease. Stroke 27: 538–543.
75. Price R. Brew B. Poke M. (1992) Central and peripheral nervous system complications in HIV-I infection and AIDS. In: Ed. Devita V. Hellman S. Rosenberg S. (eds), AIDS: Etiology, Diagnosis, Treatment and Prevention, 3rd ed. Philadelphia, PA: J.B. Lippincott Co., p. 249.
76. Qureshi A. Janssen R. Karon J. Weissman J. Akbar M. Safdar K. et al. (1997) Human immunodeficiency virus infection and stroke in young patients. Arch Neurol 54: 1150–1153.
77. Rahmanian S. Wewers M. Koletar S. Reynolds N. Ferketich A. Diaz P. (2011) Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc 8: 313–319.
78. Rasmussen L. Engsig F. Christensen H. Gerstoft J. Kronborg G. Pedersen C. et al. (2011) Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS 25: 1637–1646.
79. Sabin C. Worm S. Weber R. Reiss P. El-Sadr W. Dabis F. et al. (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371: 1417–1426.
80. Sacktor N. Lyles R. Skolasky R. Kleeberger C. Selnes O. Miller E. et al. (2001) HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990–1998. Neurology 56: 257–260.
81. Saif M. Greenberg B. (2001) HIV and thrombosis: a review. AIDS Patient Care STDs 15: 15–24.
82. Seaberg E. Benning L. Sharrett A. Lazar J. Hodis H. Mack W. et al. (2010) Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke 41: 2163–2170.
83. Sen S. Rabinstein A. Elkind M. Powers W. (2012) Recent developments regarding human immunodeficiency virus infection and stroke. Cerebrovasc Dis 33: 209–218.
84. Strazza M. Pirrone V. Wigdahl B. Nonnemacher M. (2011) Breaking down the barrier: the effects of HIV-1 on the blood–brain barrier. Brain Res 1399: 96–115.
85. Subsai K. Kanoksri S. Siwaporn C. Helen L. Kanokporn O. Wantana P. (2006) Neurological complications in AIDS patients receiving HAART: a 2-year retrospective study. Eur J Neurol 13: 233–239.
86. Tipping B. de Villiers L. Candy S. Wainwright H. (2006) Stroke caused by human immunodeficiency virus-associated intracranial large-vessel aneurysmal vasculopathy. Arch Neurol 63: 1640–1642.
87. Tipping B. de Villiers L. Wainwright H. Candy S. Bryer A. (2007) Stroke in patients with human immunodeficiency virus infection. J Neurol Neurosurg Psychiatry 78: 1320–1324.
88. Toborek M. Lee Y. Flora G. Pu H. Andras I. Wylegala E. et al. (2005) Mechanisms of the blood–brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 25: 181–199.
89. Tornero C. Mafe C. (2009) Varenicline and antiretroviral therapy in patients with HIV. J Acquir Immune Defic Syndr 52: 656.
90. Tornero C. Ventura A. Mafe M. (2010) Aspirin is indicated for primary prevention of cardiovascular events in HIV-infected patients. J Acquir Immune Defic Syndr 54: 560.
91. Vila E. Salaices M. (2005) Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol 288: H1016–H1021.
92. Wardlaw J. Murray V. Berge E. del Zoppo G. Sandercock P. Lindley R. et al. (2012) Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379: 2364–2372.
93. Worm S. Kamara D. Reiss P. Fontas E. de Wit S. El-Sadr W. et al. (2012) Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. J Infect Dis 205: 535–539.
94. Worm S. Sabin C. Weber R. Reiss P. El-Sadr W. Dabis F. et al. (2010) Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 201: 318–330.
95. Zanni M. Grinspoon S. (2012) HIV-specific immune dysregulation and atherosclerosis. Curr HIV / AIDS Rep 9: 200–205.